Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Kathy Miller, Molin Wang, Julie Gralow, Maura Dickler, Melody Cobleigh, Edith A. Perez, Tamara Shenkier, David Cella, Nancy E. Davidson

Research output: Contribution to journalArticle

2434 Citations (Scopus)

Abstract

BACKGROUND: In an open-label, randomized, phase 3 trial, we compared the efficacy and safety of paclitaxel with that of paclitaxel plus bevacizumab, a monoclonal antibody against vascular endothelial growth factor, as initial treatment for metastatic breast cancer. METHODS: We randomly assigned patients to receive 90 mg of paclitaxel per square meter of body-surface area on days 1, 8, and 15 every 4 weeks, either alone or with 10 mg of bevacizumab per kilogram of body weight on days 1 and 15. The primary end point was progression-free survival; overall survival was a secondary end point. RESULTS: From December 2001 through May 2004, a total of 722 patients were enrolled. Paclitaxel plus bevacizumab significantly prolonged progression-free survival as compared with paclitaxel alone (median, 11.8 vs. 5.9 months; hazard ratio for progression, 0.60; P<0.001) and increased the objective response rate (36.9% vs. 21.2%, P<0.001). The overall survival rate, however, was similar in the two groups (median, 26.7 vs. 25.2 months; hazard ratio, 0.88; P = 0.16). Grade 3 or 4 hypertension (14.8% vs. 0.0%, P<0.001), proteinuria (3.6% vs. 0.0%, P<0.001), headache (2.2% vs. 0.0%, P = 0.008), and cerebrovascular ischemia (1.9% vs. 0.0%, P = 0.02) were more frequent in patients receiving paclitaxel plus bevacizumab. Infection was more common in patients receiving paclitaxel plus bevacizumab (9.3% vs. 2.9%, P<0.001), but febrile neutropenia was uncommon (<1% overall). CONCLUSIONS: Initial therapy of metastatic breast cancer with paclitaxel plus bevacizumab prolongs progression-free survival, but not overall survival, as compared with paclitaxel alone. (ClinicalTrials.gov number, NCT00028990.)

Original languageEnglish (US)
Pages (from-to)2666-2676
Number of pages11
JournalNew England Journal of Medicine
Volume357
Issue number26
DOIs
StatePublished - Dec 27 2007

Fingerprint

Paclitaxel
Breast Neoplasms
Disease-Free Survival
Bevacizumab
Febrile Neutropenia
Survival
Body Surface Area
Proteinuria
Vascular Endothelial Growth Factor A
Headache
Ischemia
Survival Rate
Monoclonal Antibodies
Body Weight
Hypertension
Safety
Therapeutics
Infection

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., ... Davidson, N. E. (2007). Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. New England Journal of Medicine, 357(26), 2666-2676. https://doi.org/10.1056/NEJMoa072113

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. / Miller, Kathy; Wang, Molin; Gralow, Julie; Dickler, Maura; Cobleigh, Melody; Perez, Edith A.; Shenkier, Tamara; Cella, David; Davidson, Nancy E.

In: New England Journal of Medicine, Vol. 357, No. 26, 27.12.2007, p. 2666-2676.

Research output: Contribution to journalArticle

Miller, K, Wang, M, Gralow, J, Dickler, M, Cobleigh, M, Perez, EA, Shenkier, T, Cella, D & Davidson, NE 2007, 'Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer', New England Journal of Medicine, vol. 357, no. 26, pp. 2666-2676. https://doi.org/10.1056/NEJMoa072113
Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. New England Journal of Medicine. 2007 Dec 27;357(26):2666-2676. https://doi.org/10.1056/NEJMoa072113
Miller, Kathy ; Wang, Molin ; Gralow, Julie ; Dickler, Maura ; Cobleigh, Melody ; Perez, Edith A. ; Shenkier, Tamara ; Cella, David ; Davidson, Nancy E. / Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. In: New England Journal of Medicine. 2007 ; Vol. 357, No. 26. pp. 2666-2676.
@article{07c2846d3263453ab0bed1984c1961fd,
title = "Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer",
abstract = "BACKGROUND: In an open-label, randomized, phase 3 trial, we compared the efficacy and safety of paclitaxel with that of paclitaxel plus bevacizumab, a monoclonal antibody against vascular endothelial growth factor, as initial treatment for metastatic breast cancer. METHODS: We randomly assigned patients to receive 90 mg of paclitaxel per square meter of body-surface area on days 1, 8, and 15 every 4 weeks, either alone or with 10 mg of bevacizumab per kilogram of body weight on days 1 and 15. The primary end point was progression-free survival; overall survival was a secondary end point. RESULTS: From December 2001 through May 2004, a total of 722 patients were enrolled. Paclitaxel plus bevacizumab significantly prolonged progression-free survival as compared with paclitaxel alone (median, 11.8 vs. 5.9 months; hazard ratio for progression, 0.60; P<0.001) and increased the objective response rate (36.9{\%} vs. 21.2{\%}, P<0.001). The overall survival rate, however, was similar in the two groups (median, 26.7 vs. 25.2 months; hazard ratio, 0.88; P = 0.16). Grade 3 or 4 hypertension (14.8{\%} vs. 0.0{\%}, P<0.001), proteinuria (3.6{\%} vs. 0.0{\%}, P<0.001), headache (2.2{\%} vs. 0.0{\%}, P = 0.008), and cerebrovascular ischemia (1.9{\%} vs. 0.0{\%}, P = 0.02) were more frequent in patients receiving paclitaxel plus bevacizumab. Infection was more common in patients receiving paclitaxel plus bevacizumab (9.3{\%} vs. 2.9{\%}, P<0.001), but febrile neutropenia was uncommon (<1{\%} overall). CONCLUSIONS: Initial therapy of metastatic breast cancer with paclitaxel plus bevacizumab prolongs progression-free survival, but not overall survival, as compared with paclitaxel alone. (ClinicalTrials.gov number, NCT00028990.)",
author = "Kathy Miller and Molin Wang and Julie Gralow and Maura Dickler and Melody Cobleigh and Perez, {Edith A.} and Tamara Shenkier and David Cella and Davidson, {Nancy E.}",
year = "2007",
month = "12",
day = "27",
doi = "10.1056/NEJMoa072113",
language = "English (US)",
volume = "357",
pages = "2666--2676",
journal = "New England Journal of Medicine",
issn = "1533-4406",
publisher = "Massachussetts Medical Society",
number = "26",

}

TY - JOUR

T1 - Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

AU - Miller, Kathy

AU - Wang, Molin

AU - Gralow, Julie

AU - Dickler, Maura

AU - Cobleigh, Melody

AU - Perez, Edith A.

AU - Shenkier, Tamara

AU - Cella, David

AU - Davidson, Nancy E.

PY - 2007/12/27

Y1 - 2007/12/27

N2 - BACKGROUND: In an open-label, randomized, phase 3 trial, we compared the efficacy and safety of paclitaxel with that of paclitaxel plus bevacizumab, a monoclonal antibody against vascular endothelial growth factor, as initial treatment for metastatic breast cancer. METHODS: We randomly assigned patients to receive 90 mg of paclitaxel per square meter of body-surface area on days 1, 8, and 15 every 4 weeks, either alone or with 10 mg of bevacizumab per kilogram of body weight on days 1 and 15. The primary end point was progression-free survival; overall survival was a secondary end point. RESULTS: From December 2001 through May 2004, a total of 722 patients were enrolled. Paclitaxel plus bevacizumab significantly prolonged progression-free survival as compared with paclitaxel alone (median, 11.8 vs. 5.9 months; hazard ratio for progression, 0.60; P<0.001) and increased the objective response rate (36.9% vs. 21.2%, P<0.001). The overall survival rate, however, was similar in the two groups (median, 26.7 vs. 25.2 months; hazard ratio, 0.88; P = 0.16). Grade 3 or 4 hypertension (14.8% vs. 0.0%, P<0.001), proteinuria (3.6% vs. 0.0%, P<0.001), headache (2.2% vs. 0.0%, P = 0.008), and cerebrovascular ischemia (1.9% vs. 0.0%, P = 0.02) were more frequent in patients receiving paclitaxel plus bevacizumab. Infection was more common in patients receiving paclitaxel plus bevacizumab (9.3% vs. 2.9%, P<0.001), but febrile neutropenia was uncommon (<1% overall). CONCLUSIONS: Initial therapy of metastatic breast cancer with paclitaxel plus bevacizumab prolongs progression-free survival, but not overall survival, as compared with paclitaxel alone. (ClinicalTrials.gov number, NCT00028990.)

AB - BACKGROUND: In an open-label, randomized, phase 3 trial, we compared the efficacy and safety of paclitaxel with that of paclitaxel plus bevacizumab, a monoclonal antibody against vascular endothelial growth factor, as initial treatment for metastatic breast cancer. METHODS: We randomly assigned patients to receive 90 mg of paclitaxel per square meter of body-surface area on days 1, 8, and 15 every 4 weeks, either alone or with 10 mg of bevacizumab per kilogram of body weight on days 1 and 15. The primary end point was progression-free survival; overall survival was a secondary end point. RESULTS: From December 2001 through May 2004, a total of 722 patients were enrolled. Paclitaxel plus bevacizumab significantly prolonged progression-free survival as compared with paclitaxel alone (median, 11.8 vs. 5.9 months; hazard ratio for progression, 0.60; P<0.001) and increased the objective response rate (36.9% vs. 21.2%, P<0.001). The overall survival rate, however, was similar in the two groups (median, 26.7 vs. 25.2 months; hazard ratio, 0.88; P = 0.16). Grade 3 or 4 hypertension (14.8% vs. 0.0%, P<0.001), proteinuria (3.6% vs. 0.0%, P<0.001), headache (2.2% vs. 0.0%, P = 0.008), and cerebrovascular ischemia (1.9% vs. 0.0%, P = 0.02) were more frequent in patients receiving paclitaxel plus bevacizumab. Infection was more common in patients receiving paclitaxel plus bevacizumab (9.3% vs. 2.9%, P<0.001), but febrile neutropenia was uncommon (<1% overall). CONCLUSIONS: Initial therapy of metastatic breast cancer with paclitaxel plus bevacizumab prolongs progression-free survival, but not overall survival, as compared with paclitaxel alone. (ClinicalTrials.gov number, NCT00028990.)

UR - http://www.scopus.com/inward/record.url?scp=37549040613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549040613&partnerID=8YFLogxK

U2 - 10.1056/NEJMoa072113

DO - 10.1056/NEJMoa072113

M3 - Article

C2 - 18160686

AN - SCOPUS:37549040613

VL - 357

SP - 2666

EP - 2676

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 1533-4406

IS - 26

ER -